Review



recombinant mouse scd163  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 92
      Buy from Supplier

    Structured Review

    R&D Systems recombinant mouse scd163
    Figure 4 | TWEAK activates canonical NF-jB signalling and Notch activation and mediates the response of CD163 / mice to HLI. (a) Analysis of plasma from WT and CD163 / mice before and after femoral ligation for TWEAK and <t>sCD163</t> levels by ELISA (n ¼ 5 per group). (b) Laser doppler analysis of CD163 / mice 3, 7, 14, 21 and 28 days after femoral ligation administered an isotype control or TWEAK blocking antibody (n ¼ 5 per group). (c) Immunoblotting of CD163 / IL at 14 days after femoral ligation with administration of isotype control or TWEAK blocking antibody (n ¼ 5 per group) with graphs showing quantitation of densitometry for phosphorylated/total p65 and NICD below. (d) Immunostaining for VE-cadherin (green) and b- dystroglycan (red) in CD163 / limbs with 14 day administration of TWEAK (5 or 25 mg kg 1 day 1) or saline (control) (n ¼ 5 per group). Scale bars, 100 mm. The graphs show the number of VE-cadherin positive cells/myofibre and the average muscle fibre area. (e) Immunoblotting of CD163 / limbs with 14 day administration of TWEAK (5 or 25 mg kg 1 day 1) or saline (control) (n ¼ 5 per group) with graphs showing quantitation of densitometry for phosphorylated p65/total p65, p52 and NICD. All bars show mean±s.e.m. *Po0.05 versus WT in a; versus CD163 / control in b,c and e. Po0.05 versus other groups in d,e. Comparisons between groups were achieved using a two-sided student’s t-test. For multiple group comparisons, we utilized a one-way ANOVA. If the variance ratio test (F-test) was significant, a more detailed post hoc analysis of differences between groups was made using a Tukey–Kramer honest significance difference test.
    Recombinant Mouse Scd163, supplied by R&D Systems, used in various techniques. Bioz Stars score: 92/100, based on 4 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+mouse+scd163/Recombinant+Mouse+CD163+Protein%2C+CF/pm26242746-407-0-4
    Average 92 stars, based on 4 article reviews
    recombinant mouse scd163 - by Bioz Stars, 2026-09
    92/100 stars

    Images

    1) Product Images from "CD163 interacts with TWEAK to regulate tissue regeneration after ischaemic injury."

    Article Title: CD163 interacts with TWEAK to regulate tissue regeneration after ischaemic injury.

    Journal: Nature communications

    doi: 10.1038/ncomms8792

    Figure 4 | TWEAK activates canonical NF-jB signalling and Notch activation and mediates the response of CD163 / mice to HLI. (a) Analysis of plasma from WT and CD163 / mice before and after femoral ligation for TWEAK and sCD163 levels by ELISA (n ¼ 5 per group). (b) Laser doppler analysis of CD163 / mice 3, 7, 14, 21 and 28 days after femoral ligation administered an isotype control or TWEAK blocking antibody (n ¼ 5 per group). (c) Immunoblotting of CD163 / IL at 14 days after femoral ligation with administration of isotype control or TWEAK blocking antibody (n ¼ 5 per group) with graphs showing quantitation of densitometry for phosphorylated/total p65 and NICD below. (d) Immunostaining for VE-cadherin (green) and b- dystroglycan (red) in CD163 / limbs with 14 day administration of TWEAK (5 or 25 mg kg 1 day 1) or saline (control) (n ¼ 5 per group). Scale bars, 100 mm. The graphs show the number of VE-cadherin positive cells/myofibre and the average muscle fibre area. (e) Immunoblotting of CD163 / limbs with 14 day administration of TWEAK (5 or 25 mg kg 1 day 1) or saline (control) (n ¼ 5 per group) with graphs showing quantitation of densitometry for phosphorylated p65/total p65, p52 and NICD. All bars show mean±s.e.m. *Po0.05 versus WT in a; versus CD163 / control in b,c and e. Po0.05 versus other groups in d,e. Comparisons between groups were achieved using a two-sided student’s t-test. For multiple group comparisons, we utilized a one-way ANOVA. If the variance ratio test (F-test) was significant, a more detailed post hoc analysis of differences between groups was made using a Tukey–Kramer honest significance difference test.
    Figure Legend Snippet: Figure 4 | TWEAK activates canonical NF-jB signalling and Notch activation and mediates the response of CD163 / mice to HLI. (a) Analysis of plasma from WT and CD163 / mice before and after femoral ligation for TWEAK and sCD163 levels by ELISA (n ¼ 5 per group). (b) Laser doppler analysis of CD163 / mice 3, 7, 14, 21 and 28 days after femoral ligation administered an isotype control or TWEAK blocking antibody (n ¼ 5 per group). (c) Immunoblotting of CD163 / IL at 14 days after femoral ligation with administration of isotype control or TWEAK blocking antibody (n ¼ 5 per group) with graphs showing quantitation of densitometry for phosphorylated/total p65 and NICD below. (d) Immunostaining for VE-cadherin (green) and b- dystroglycan (red) in CD163 / limbs with 14 day administration of TWEAK (5 or 25 mg kg 1 day 1) or saline (control) (n ¼ 5 per group). Scale bars, 100 mm. The graphs show the number of VE-cadherin positive cells/myofibre and the average muscle fibre area. (e) Immunoblotting of CD163 / limbs with 14 day administration of TWEAK (5 or 25 mg kg 1 day 1) or saline (control) (n ¼ 5 per group) with graphs showing quantitation of densitometry for phosphorylated p65/total p65, p52 and NICD. All bars show mean±s.e.m. *Po0.05 versus WT in a; versus CD163 / control in b,c and e. Po0.05 versus other groups in d,e. Comparisons between groups were achieved using a two-sided student’s t-test. For multiple group comparisons, we utilized a one-way ANOVA. If the variance ratio test (F-test) was significant, a more detailed post hoc analysis of differences between groups was made using a Tukey–Kramer honest significance difference test.

    Techniques Used: Activation Assay, Clinical Proteomics, Ligation, Enzyme-linked Immunosorbent Assay, Control, Blocking Assay, Western Blot, Quantitation Assay, Immunostaining, Saline

    Figure 6 | sCD163 inhibits the effect of TWEAK on tissue regeneration. (a) TWEAK (100 ng ml 1) was added to VEGFR1, Fn14 or CD163-coated wells. Bound protein was measured by ELISA using an antibody to detect TWEAK. (b) Fn14 or CD163 were coated onto 96-well plates and incubated with increasing doses of untagged TWEAK. Bound protein was measured by ELISA. (c) Immunoblotting of MDEC stimulated with TWEAK at 200 ng ml 1
    Figure Legend Snippet: Figure 6 | sCD163 inhibits the effect of TWEAK on tissue regeneration. (a) TWEAK (100 ng ml 1) was added to VEGFR1, Fn14 or CD163-coated wells. Bound protein was measured by ELISA using an antibody to detect TWEAK. (b) Fn14 or CD163 were coated onto 96-well plates and incubated with increasing doses of untagged TWEAK. Bound protein was measured by ELISA. (c) Immunoblotting of MDEC stimulated with TWEAK at 200 ng ml 1

    Techniques Used: Enzyme-linked Immunosorbent Assay, Incubation, Western Blot

    Figure 7 | CD163-TWEAK interaction controls skeletal muscle recovery after ischaemic injury. After ischaemic injury, macrophages secrete TWEAK which induces tissue canonical NF-KB/Notch mediated myogenic progenitor cell proliferation. TWEAK’s biological activity is tightly regulated by sCD163 binding which limits serum TWEAK levels and leads to resolution of canonical NF-kB/Notch activation at the site of injury, allowing for cell differentiation. In the absence of sCD163 (as seen in CD163-deficient mice), TWEAK levels are systemically elevated and TWEAK’s biological effect is unopposed leading to prolonged activation of NF-kB and Notch signalling which causes greater myogenic progenitor cell proliferation-induced myogenesis not limited to the site of injury.
    Figure Legend Snippet: Figure 7 | CD163-TWEAK interaction controls skeletal muscle recovery after ischaemic injury. After ischaemic injury, macrophages secrete TWEAK which induces tissue canonical NF-KB/Notch mediated myogenic progenitor cell proliferation. TWEAK’s biological activity is tightly regulated by sCD163 binding which limits serum TWEAK levels and leads to resolution of canonical NF-kB/Notch activation at the site of injury, allowing for cell differentiation. In the absence of sCD163 (as seen in CD163-deficient mice), TWEAK levels are systemically elevated and TWEAK’s biological effect is unopposed leading to prolonged activation of NF-kB and Notch signalling which causes greater myogenic progenitor cell proliferation-induced myogenesis not limited to the site of injury.

    Techniques Used: Activity Assay, Binding Assay, Activation Assay, Cell Differentiation

    Related Articles

    Recombinant:

    Article Title: CD163 interacts with TWEAK to regulate tissue regeneration after ischaemic injury
    Article Snippet: .. Recombinant mouse sCD163 (cat#7435 R&D Systems) and recombinant soluble Fn14/TWEAKR (cat#310-21Peprotech) were coated onto 96-well microtiter plate (Linbro MP Biomedicals) at a concentration of 1 μg ml −1 in bicarbonate/carbonate buffer (pH 9) overnight at 4 °C. .. VEGFR1 (cat#10136-H08H Life technologies) was used as a negative control.

    Article Title: CD163 interacts with TWEAK to regulate tissue regeneration after ischaemic injury.
    Article Snippet: .. Recombinant mouse sCD163 (cat#7435 R&D Systems) and recombinant soluble Fn14/TWEAKR (cat#310-21Peprotech) were coated onto 96-well microtiter plate (Linbro MP Biomedicals) at a concentration of 1 mgml 1 in bicarbonate/carbonate buffer (pH 9) overnight at 4 C. VEGFR1 (cat#10136H08H Life technologies) was used as a negative control. .. Wells were blocked with blocking buffer (Pierce) in phosphate buffered saline with 0.05% Tween 20 (PBST) for 1 h. PBST was used as wash buffer.

    Concentration Assay:

    Article Title: CD163 interacts with TWEAK to regulate tissue regeneration after ischaemic injury
    Article Snippet: .. Recombinant mouse sCD163 (cat#7435 R&D Systems) and recombinant soluble Fn14/TWEAKR (cat#310-21Peprotech) were coated onto 96-well microtiter plate (Linbro MP Biomedicals) at a concentration of 1 μg ml −1 in bicarbonate/carbonate buffer (pH 9) overnight at 4 °C. .. VEGFR1 (cat#10136-H08H Life technologies) was used as a negative control.

    Article Title: CD163 interacts with TWEAK to regulate tissue regeneration after ischaemic injury.
    Article Snippet: .. Recombinant mouse sCD163 (cat#7435 R&D Systems) and recombinant soluble Fn14/TWEAKR (cat#310-21Peprotech) were coated onto 96-well microtiter plate (Linbro MP Biomedicals) at a concentration of 1 mgml 1 in bicarbonate/carbonate buffer (pH 9) overnight at 4 C. VEGFR1 (cat#10136H08H Life technologies) was used as a negative control. .. Wells were blocked with blocking buffer (Pierce) in phosphate buffered saline with 0.05% Tween 20 (PBST) for 1 h. PBST was used as wash buffer.

    Negative Control:

    Article Title: CD163 interacts with TWEAK to regulate tissue regeneration after ischaemic injury.
    Article Snippet: .. Recombinant mouse sCD163 (cat#7435 R&D Systems) and recombinant soluble Fn14/TWEAKR (cat#310-21Peprotech) were coated onto 96-well microtiter plate (Linbro MP Biomedicals) at a concentration of 1 mgml 1 in bicarbonate/carbonate buffer (pH 9) overnight at 4 C. VEGFR1 (cat#10136H08H Life technologies) was used as a negative control. .. Wells were blocked with blocking buffer (Pierce) in phosphate buffered saline with 0.05% Tween 20 (PBST) for 1 h. PBST was used as wash buffer.



    Similar Products

    recombinant mouse scd163  (R&D Systems)
    92
    R&D Systems recombinant mouse scd163
    Figure 4 | TWEAK activates canonical NF-jB signalling and Notch activation and mediates the response of CD163 / mice to HLI. (a) Analysis of plasma from WT and CD163 / mice before and after femoral ligation for TWEAK and <t>sCD163</t> levels by ELISA (n ¼ 5 per group). (b) Laser doppler analysis of CD163 / mice 3, 7, 14, 21 and 28 days after femoral ligation administered an isotype control or TWEAK blocking antibody (n ¼ 5 per group). (c) Immunoblotting of CD163 / IL at 14 days after femoral ligation with administration of isotype control or TWEAK blocking antibody (n ¼ 5 per group) with graphs showing quantitation of densitometry for phosphorylated/total p65 and NICD below. (d) Immunostaining for VE-cadherin (green) and b- dystroglycan (red) in CD163 / limbs with 14 day administration of TWEAK (5 or 25 mg kg 1 day 1) or saline (control) (n ¼ 5 per group). Scale bars, 100 mm. The graphs show the number of VE-cadherin positive cells/myofibre and the average muscle fibre area. (e) Immunoblotting of CD163 / limbs with 14 day administration of TWEAK (5 or 25 mg kg 1 day 1) or saline (control) (n ¼ 5 per group) with graphs showing quantitation of densitometry for phosphorylated p65/total p65, p52 and NICD. All bars show mean±s.e.m. *Po0.05 versus WT in a; versus CD163 / control in b,c and e. Po0.05 versus other groups in d,e. Comparisons between groups were achieved using a two-sided student’s t-test. For multiple group comparisons, we utilized a one-way ANOVA. If the variance ratio test (F-test) was significant, a more detailed post hoc analysis of differences between groups was made using a Tukey–Kramer honest significance difference test.
    Recombinant Mouse Scd163, supplied by R&D Systems, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+mouse+scd163/Recombinant+Mouse+CD163+Protein%2C+CF/pm26242746-407-0-4
    Average 92 stars, based on 1 article reviews
    recombinant mouse scd163 - by Bioz Stars, 2026-09
    92/100 stars
    		  Buy from Supplier

    Image Search Results


    Figure 4 | TWEAK activates canonical NF-jB signalling and Notch activation and mediates the response of CD163 / mice to HLI. (a) Analysis of plasma from WT and CD163 / mice before and after femoral ligation for TWEAK and sCD163 levels by ELISA (n ¼ 5 per group). (b) Laser doppler analysis of CD163 / mice 3, 7, 14, 21 and 28 days after femoral ligation administered an isotype control or TWEAK blocking antibody (n ¼ 5 per group). (c) Immunoblotting of CD163 / IL at 14 days after femoral ligation with administration of isotype control or TWEAK blocking antibody (n ¼ 5 per group) with graphs showing quantitation of densitometry for phosphorylated/total p65 and NICD below. (d) Immunostaining for VE-cadherin (green) and b- dystroglycan (red) in CD163 / limbs with 14 day administration of TWEAK (5 or 25 mg kg 1 day 1) or saline (control) (n ¼ 5 per group). Scale bars, 100 mm. The graphs show the number of VE-cadherin positive cells/myofibre and the average muscle fibre area. (e) Immunoblotting of CD163 / limbs with 14 day administration of TWEAK (5 or 25 mg kg 1 day 1) or saline (control) (n ¼ 5 per group) with graphs showing quantitation of densitometry for phosphorylated p65/total p65, p52 and NICD. All bars show mean±s.e.m. *Po0.05 versus WT in a; versus CD163 / control in b,c and e. Po0.05 versus other groups in d,e. Comparisons between groups were achieved using a two-sided student’s t-test. For multiple group comparisons, we utilized a one-way ANOVA. If the variance ratio test (F-test) was significant, a more detailed post hoc analysis of differences between groups was made using a Tukey–Kramer honest significance difference test.

    Journal: Nature communications

    Article Title: CD163 interacts with TWEAK to regulate tissue regeneration after ischaemic injury.

    doi: 10.1038/ncomms8792

    Figure Lengend Snippet: Figure 4 | TWEAK activates canonical NF-jB signalling and Notch activation and mediates the response of CD163 / mice to HLI. (a) Analysis of plasma from WT and CD163 / mice before and after femoral ligation for TWEAK and sCD163 levels by ELISA (n ¼ 5 per group). (b) Laser doppler analysis of CD163 / mice 3, 7, 14, 21 and 28 days after femoral ligation administered an isotype control or TWEAK blocking antibody (n ¼ 5 per group). (c) Immunoblotting of CD163 / IL at 14 days after femoral ligation with administration of isotype control or TWEAK blocking antibody (n ¼ 5 per group) with graphs showing quantitation of densitometry for phosphorylated/total p65 and NICD below. (d) Immunostaining for VE-cadherin (green) and b- dystroglycan (red) in CD163 / limbs with 14 day administration of TWEAK (5 or 25 mg kg 1 day 1) or saline (control) (n ¼ 5 per group). Scale bars, 100 mm. The graphs show the number of VE-cadherin positive cells/myofibre and the average muscle fibre area. (e) Immunoblotting of CD163 / limbs with 14 day administration of TWEAK (5 or 25 mg kg 1 day 1) or saline (control) (n ¼ 5 per group) with graphs showing quantitation of densitometry for phosphorylated p65/total p65, p52 and NICD. All bars show mean±s.e.m. *Po0.05 versus WT in a; versus CD163 / control in b,c and e. Po0.05 versus other groups in d,e. Comparisons between groups were achieved using a two-sided student’s t-test. For multiple group comparisons, we utilized a one-way ANOVA. If the variance ratio test (F-test) was significant, a more detailed post hoc analysis of differences between groups was made using a Tukey–Kramer honest significance difference test.

    Article Snippet: Recombinant mouse sCD163 (cat#7435 R&D Systems) and recombinant soluble Fn14/TWEAKR (cat#310-21Peprotech) were coated onto 96-well microtiter plate (Linbro MP Biomedicals) at a concentration of 1 mgml 1 in bicarbonate/carbonate buffer (pH 9) overnight at 4 C. VEGFR1 (cat#10136H08H Life technologies) was used as a negative control.

    Techniques: Activation Assay, Clinical Proteomics, Ligation, Enzyme-linked Immunosorbent Assay, Control, Blocking Assay, Western Blot, Quantitation Assay, Immunostaining, Saline

    Figure 6 | sCD163 inhibits the effect of TWEAK on tissue regeneration. (a) TWEAK (100 ng ml 1) was added to VEGFR1, Fn14 or CD163-coated wells. Bound protein was measured by ELISA using an antibody to detect TWEAK. (b) Fn14 or CD163 were coated onto 96-well plates and incubated with increasing doses of untagged TWEAK. Bound protein was measured by ELISA. (c) Immunoblotting of MDEC stimulated with TWEAK at 200 ng ml 1

    Journal: Nature communications

    Article Title: CD163 interacts with TWEAK to regulate tissue regeneration after ischaemic injury.

    doi: 10.1038/ncomms8792

    Figure Lengend Snippet: Figure 6 | sCD163 inhibits the effect of TWEAK on tissue regeneration. (a) TWEAK (100 ng ml 1) was added to VEGFR1, Fn14 or CD163-coated wells. Bound protein was measured by ELISA using an antibody to detect TWEAK. (b) Fn14 or CD163 were coated onto 96-well plates and incubated with increasing doses of untagged TWEAK. Bound protein was measured by ELISA. (c) Immunoblotting of MDEC stimulated with TWEAK at 200 ng ml 1

    Article Snippet: Recombinant mouse sCD163 (cat#7435 R&D Systems) and recombinant soluble Fn14/TWEAKR (cat#310-21Peprotech) were coated onto 96-well microtiter plate (Linbro MP Biomedicals) at a concentration of 1 mgml 1 in bicarbonate/carbonate buffer (pH 9) overnight at 4 C. VEGFR1 (cat#10136H08H Life technologies) was used as a negative control.

    Techniques: Enzyme-linked Immunosorbent Assay, Incubation, Western Blot

    Figure 7 | CD163-TWEAK interaction controls skeletal muscle recovery after ischaemic injury. After ischaemic injury, macrophages secrete TWEAK which induces tissue canonical NF-KB/Notch mediated myogenic progenitor cell proliferation. TWEAK’s biological activity is tightly regulated by sCD163 binding which limits serum TWEAK levels and leads to resolution of canonical NF-kB/Notch activation at the site of injury, allowing for cell differentiation. In the absence of sCD163 (as seen in CD163-deficient mice), TWEAK levels are systemically elevated and TWEAK’s biological effect is unopposed leading to prolonged activation of NF-kB and Notch signalling which causes greater myogenic progenitor cell proliferation-induced myogenesis not limited to the site of injury.

    Journal: Nature communications

    Article Title: CD163 interacts with TWEAK to regulate tissue regeneration after ischaemic injury.

    doi: 10.1038/ncomms8792

    Figure Lengend Snippet: Figure 7 | CD163-TWEAK interaction controls skeletal muscle recovery after ischaemic injury. After ischaemic injury, macrophages secrete TWEAK which induces tissue canonical NF-KB/Notch mediated myogenic progenitor cell proliferation. TWEAK’s biological activity is tightly regulated by sCD163 binding which limits serum TWEAK levels and leads to resolution of canonical NF-kB/Notch activation at the site of injury, allowing for cell differentiation. In the absence of sCD163 (as seen in CD163-deficient mice), TWEAK levels are systemically elevated and TWEAK’s biological effect is unopposed leading to prolonged activation of NF-kB and Notch signalling which causes greater myogenic progenitor cell proliferation-induced myogenesis not limited to the site of injury.

    Article Snippet: Recombinant mouse sCD163 (cat#7435 R&D Systems) and recombinant soluble Fn14/TWEAKR (cat#310-21Peprotech) were coated onto 96-well microtiter plate (Linbro MP Biomedicals) at a concentration of 1 mgml 1 in bicarbonate/carbonate buffer (pH 9) overnight at 4 C. VEGFR1 (cat#10136H08H Life technologies) was used as a negative control.

    Techniques: Activity Assay, Binding Assay, Activation Assay, Cell Differentiation